Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6-7/2017

01-10-2017 | Research Paper

Current chemotherapeutic regimens for brain metastases treatment

Authors: Joo Yeon Nam, Barbara J. O’Brien

Published in: Clinical & Experimental Metastasis | Issue 6-7/2017

Login to get access

Abstract

Brain metastasis is a common complication in advanced systemic cancer, with an increasing incidence. The diagnosis of brain metastasis historically portended a dismal prognosis. The successful development of effective treatments for patients with brain metastasis is complicated by the differences among cancer subtypes, the limited understanding of the underlying pathophysiology of BM, the impact of the blood-brain barrier, and other factors. There is now renewed interest in treating this often devastating complication of cancer, and in understanding the underlying mechanisms of disease in this “sanctuary” site. Promising treatment strategies include brain-penetrant targeted therapies and immunotherapy, and strategies for enhanced delivery of therapy. This review highlights a selection of these approaches.
Literature
1.
2.
Pérez-Larraya JG, Hildebrand J (2014) Brain metastases. Handb Clin Neurol 121:1143–1157CrossRef
3.
Parrish KE, Sarkaria JN, Elmquist WF (2015) Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin Pharmacol Ther 97(4):336–346CrossRefPubMed
4.
Maher EA et al (2009) Brain metastasis: opportunities in basic and translational research. Cancer Res 69(15):6015–6020CrossRefPubMed
5.
6.
Azim H, Azim HA Jr (2008) Targeting Her-2/neu in breast cancer: as easy as this!. Oncology 74(3–4):150–157CrossRefPubMed
7.
Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27(31):5278–5286CrossRefPubMed
8.
Brufsky AM et al (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834–4843CrossRefPubMed
9.
Stemmler HJ et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15(2):219–225CrossRefPubMed
10.
Yau T et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45(2):196–201CrossRefPubMed
11.
12.
13.
Gelmon KA et al (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33(14):1574–1583CrossRefPubMed
14.
Pivot X et al (2015) CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33(14):1564–1573CrossRefPubMed
15.
Lin NU et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12):1993–1999CrossRefPubMedPubMedCentral
16.
Lin NU et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459CrossRefPubMed
17.
Cameron D et al (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15(9):924–934CrossRefPubMedPubMedCentral
18.
Lin NU et al (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105(3):613–620CrossRefPubMed
19.
Sutherland S et al (2010) Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases–the UK experience. Br J Cancer 102(6):995–1002CrossRefPubMedPubMedCentral
20.
Metro G et al (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22(3):625–630CrossRefPubMed
21.
Bachelot T et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71CrossRefPubMed
22.
Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471CrossRefPubMedPubMedCentral
23.
Kalsi R et al (2015) Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin Breast Cancer 15(2):e163-6CrossRefPubMed
24.
Keith KC et al (2016) Activity of trastuzumab-emtansine (Tdm1) in Her2-positive breast cancer brain metastases: a case series. Cancer Treat Commun 7:43–46CrossRefPubMedPubMedCentral
25.
Krop IE et al (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26(1):113–119CrossRefPubMed
26.
Kawaguchi T et al (2016) Prospective analysis of oncogenic driver mutations and environmental factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 34(19):2247–2257CrossRefPubMed
27.
Shi Y et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154–162CrossRefPubMedPubMedCentral
28.
Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550CrossRef
29.
Eichler AF et al (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12(11):1193–1199CrossRefPubMedPubMedCentral
30.
Togashi Y et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399–405CrossRefPubMed
31.
Zhao J et al (2013) Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 14(2):188–193CrossRefPubMed
32.
Deng Y et al (2014) The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol 2(1):116–120CrossRefPubMed
33.
Porta R et al (2011) Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37(3):624–631CrossRefPubMed
34.
Iuchi T et al (2013) Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82(2):282–287CrossRefPubMed
35.
Park SJ et al (2012) Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3):556–660CrossRefPubMed
36.
Kim JE et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65(3):351–354CrossRefPubMed
37.
Ruppert AM et al (2009) EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 33(2):436–440CrossRefPubMed
38.
Omuro AM et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103(11):2344–2348CrossRefPubMed
39.
Grommes C et al (2011) “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13(12):1364–1369CrossRefPubMedPubMedCentral
40.
Berz D et al (2017) P2.03b-016 tesevatinib in NSCLC patients with EGFR activating mutations and brain metastases (BM) or leptomeningeal metastases (LM). J Thorac Oncol. 12(1):S942–S943CrossRef
41.
Heon S et al (2012) The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 18(16):4406–4414CrossRefPubMedPubMedCentral
42.
Berger LA et al (2013) CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80(3):242–248CrossRefPubMed
43.
Hata A et al (2013) Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 119(24):4325–4332CrossRefPubMed
44.
Rossi A et al (2017) Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opin Pharmacother 18(2):151–163CrossRefPubMed
45.
Ballard P et al (2016) Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res 22(20):5130–5140CrossRefPubMed
46.
Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang Z, Jiang H, Ahn MJ (2016) Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol. doi:10.​1200/​JCO.​2016.​34.​15_​suppl.​9002
47.
48.
Sequist LV, Soria JC, Camidge DR (2016) Update to Rociletinib Data with the RECIST Confirmed Response Rate. N Engl J Med 374(23):2296–2297CrossRefPubMed
49.
Yu HA et al (2016) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. doi:10.​1093/​annonc/​mdw556
50.
Clarke JL et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283–286CrossRefPubMedPubMedCentral
51.
Yi HG et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65(1):80–94CrossRefPubMed
52.
Sperduto PW et al (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85(5):1312–1318CrossRefPubMedPubMedCentral
53.
Welsh JW et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31(7):895–902CrossRefPubMedPubMedCentral
54.
Cai L et al (2014) A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol 120(2):423–430CrossRefPubMedPubMedCentral
55.
Chen Y et al (2016) First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Cancer Sci 107(12):1800–1805CrossRefPubMedPubMedCentral
56.
Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566CrossRefPubMed
57.
Shaw AT et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394CrossRefPubMed
58.
Solomon BJ et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177CrossRefPubMed
59.
Solomon BJ et al (2016) Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 34(24):2858–2865CrossRefPubMed
60.
Doebele RC et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5):1472–1482CrossRefPubMedPubMedCentral
61.
G De Castro Jr, Crinò D.S.T., L., Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu C, Hochmair MJ, Cortot AB, Tsai C, Moro-Sibilot D, García Campelo R, Branle F, Sen P, McCulloch T, Soria J (2016) First-line ceritinib versus chemotherapy in patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). In: International Association for the Study of Lung Cancer
62.
Gadgeel SM et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15(10):1119–1128CrossRefPubMed
63.
Ignatius Ou SH et al (2014) Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 9(4):549–553CrossRefPubMed
64.
Gadgeel SM et al (2016) Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 34(34):4079–4085CrossRefPubMed
65.
Ajithkumar T et al (2015) Evolving treatment options for melanoma brain metastases. Lancet Oncol 16(13):e486–e497CrossRefPubMed
66.
Dummer R et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611–621CrossRefPubMed
67.
Dzienis MR, Atkinson VG (2014) Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res 24(4):349–353CrossRefPubMed
68.
69.
70.
Narayana A et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411–416CrossRefPubMed
71.
Falchook GS et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet 379(9829):1893–1901CrossRef
72.
Long GV et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095CrossRefPubMed
73.
74.
Long GV et al (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871–878CrossRefPubMed
75.
76.
Heller KN et al (2011) Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol 29(15_suppl):8581–8581CrossRef
77.
Knisely JP et al (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227–233CrossRefPubMed
78.
Mathew M et al (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23(3):191–195CrossRefPubMed
79.
Kiess AP et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368–375CrossRefPubMedPubMedCentral
80.
81.
Di Giacomo AM et al (2015) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 26(4):798–803CrossRefPubMed
82.
Di Giacomo AM, Maio M (2015) 12TiPA randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: the NIBIT-M2 study. Ann Oncol 26(suppl_8):viii5CrossRef
83.
Kluger HM et al (2015) Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol 33(15_suppl):9009
84.
Goldberg SB et al (2015) Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol 33(15_suppl):8035
85.
Rittmeyer A et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 389(10066):255–265CrossRef
86.
Massard C et al (2016) Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34(26):3119–3125CrossRefPubMedPubMedCentral
87.
Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3(2):90–105, 51CrossRefPubMed
88.
Kinoshita M (2006) Targeted drug delivery to the brain using focused ultrasound. Top Magn Reson Imaging 17(3):209–215CrossRefPubMed
89.
90.
Chamberlain MC (2010) Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev Neurother 10(4):547–561CrossRefPubMed
91.
Deeken JF, Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 13(6):1663–1674CrossRefPubMed
92.
Gan CW, Feng SS (2010) Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31(30):7748–7757CrossRefPubMed
93.
Aryal M et al (2015) Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model. Phys Med Biol 60(6):2511–2527CrossRefPubMedPubMedCentral
94.
Aryal M et al (2015) Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release 204:60–69CrossRefPubMedPubMedCentral
95.
Carpentier A et al (2016) Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med 8(343):343re2CrossRefPubMed
96.
Wu YL et al (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24(4):993–999CrossRefPubMed
97.
Gainor JF et al (2015) Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10(2):232–236CrossRefPubMedPubMedCentral
98.
Gibney GT et al (2015) Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Cancer Med 4(8):1205–1213CrossRefPubMedPubMedCentral
Metadata
Title
Current chemotherapeutic regimens for brain metastases treatment
Authors
Joo Yeon Nam
Barbara J. O’Brien
Publication date
01-10-2017
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6-7/2017
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-017-9861-y

Other articles of this Issue 6-7/2017

Clinical & Experimental Metastasis 6-7/2017 Go to the issue

Research Paper

Radiobiology and radiotherapy of brain metastases

Review article

The role of the neural niche in brain metastasis

Research Paper

Collective invasion in ductal and lobular breast cancer associates with distant metastasis

Research Paper

Neurosurgical management of brain metastases

Commentary

Historical perspectives on the biology of brain metastasis

Editorial

Curing brain metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits